Tigecycline in the management of post-neurosurgical spondylodiscitis: a review of eight cases
Küçük Resim Yok
Tarih
2014
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Elsevier Sci Ltd
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Background: Tigecycline is a relatively new glycylcycline antimicrobial, active in vitro against a variety of Gram-positive and Gram-negative organisms. In this study we evaluated the outcomes of spondylodiscitis cases treated with tigecycline-including therapies retrospectively. Methods: All adult (age > 18 years) cases with a diagnosis of spondylodiscitis, who were treated with a tigecycline-including therapy between 2007 and 2011, were included in the study. The primary efficacy outcome was clinical success with tigecycline at the end of induction, while the secondary efficacy outcome was maintenance of success through 3 months following completion of induction. Results: A total of eight spondylodiscitis cases fulfilled the study inclusion criteria. All cases had back pain, restricted mobility, magnetic resonance findings associated with spondylodiscitis, and microbiology or pathological findings related to spondylodiscitis. All had post-neurosurgical spondylodiscitis. In five cases, tigecycline was started in accordance with the antibacterial susceptibility results from intervertebral tissue biopsy cultures, whereas in three it was started empirically. All cases had received several different antibacterials with failure before receiving tigecycline. The mean duration of tigecycline treatment was 37 +/- 21 days. One case was lost to follow-up after 2 days of tigecycline. Primary and secondary success was achieved in the remaining seven cases. Conclusions: These limited data suggest that tigecycline may have a role in the treatment of refractory spondylodiscitis cases. (C) 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
Açıklama
Anahtar Kelimeler
Spondylitis, Nosocomial, Hospital-acquired, Healthcare-associated infection, Acinetobacter baumannii, Carbapenem-resistant
Kaynak
International Journal of Infectious Diseases
WoS Q Değeri
Q3
Scopus Q Değeri
Q1
Cilt
23
